Last reviewed · How we verify
TQB2825 Injection
TQB2825 is a humanized monoclonal antibody that targets and inhibits PD-L1, blocking its interaction with PD-1 and B7.1 to enhance anti-tumor immune responses.
TQB2825 is a humanized monoclonal antibody that targets and inhibits PD-L1, blocking its interaction with PD-1 and B7.1 to enhance anti-tumor immune responses. Used for Non-small cell lung cancer, Other solid tumors (under investigation in Phase 3).
At a glance
| Generic name | TQB2825 Injection |
|---|---|
| Sponsor | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. |
| Drug class | PD-L1 inhibitor |
| Target | PD-L1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
TQB2825 binds to programmed death ligand 1 (PD-L1) on tumor cells and immune cells, preventing the suppressive signal that tumors use to evade the immune system. By blocking the PD-L1/PD-1 axis, the drug restores T-cell activation and proliferation, enabling the body's immune system to recognize and attack cancer cells more effectively.
Approved indications
- Non-small cell lung cancer
- Other solid tumors (under investigation in Phase 3)
Common side effects
- Fatigue
- Decreased appetite
- Nausea
- Immune-related adverse events (pneumonitis, hepatitis, colitis)
Key clinical trials
- Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma (PHASE1, PHASE2)
- Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma (PHASE3)
- Phase I Clinical Trial of TQB2825 Subcutaneous Injection in CD20-positive Hematological Malignancies (PHASE1)
- Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma (PHASE2)
- Clinical Trial of TQB2825 in Subjects With CD20 Positive Hematological Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: